Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

Telehealth startups have turned to liraglutide as a cost-effective alternative to patented GLP-1 drugs like Ozempic and Zepbound after losing the ability to sell exact copies due to FDA shortages. Despite its older status, liraglutide has become a popular choice among online clinics offering weight loss and diabetes medications. Companies like Hims have recently added it to their lineup, while large compounding pharmacies are ramping up production in anticipation of increased demand. Meanwhile, other telehealth firms are cautious, either halting compounded medication sales or suing for non-compliance with patent laws.